Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale... see more

Recent & Breaking News (NDAQ:GRFS)

Shareholders Are Encouraged To Contact The Schall Law Firm About Grifols SA's Potential Securities Violations

Accesswire August 18, 2024

Allegations Against Grifols SA Are Being Investigated By The Schall Law Firm And Investors Are Invited To Join

Accesswire August 17, 2024

Grifols SA Is Being Investigated By The Schall Law Firm And Impacted Investors Are Encouraged To Join

Accesswire August 16, 2024

Grifols SA Is Being Looked Into By The Schall Law Firm And We Urge Impacted Investors To Join

Accesswire August 15, 2024

Grifols SA Is Under Investigation By The Schall Law Firm, Which Urges Impacted Investors To Engage In Dialogue

Accesswire August 14, 2024

Grifols SA Is Being Investigated By The Schall Law Firm And Impacted Investors Are Encouraged To Begin Discussions

Accesswire August 13, 2024

Grifols SA Is Being Investigated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Conversations

Accesswire August 12, 2024

Grifols SA Is Under The Schall Law Firm's Probe And Affected Investors Are Urged To Begin Conversations

Accesswire August 9, 2024

Grifols SA Is Under Investigation By The Schall Law Firm, Which Urges Impacted Investors To Initiate Dialogue

Accesswire August 7, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire August 6, 2024

Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again - Hagens Berman

Business Wire August 2, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 30, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 29, 2024

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

GlobeNewswire July 29, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 26, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 25, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 24, 2024

Grifols SA Investigated By The Schall Law Firm Urges Impacted Investors To Engage In Dialogue

Accesswire July 23, 2024

Grifols SA Under Investigation By The Schall Law Firm Encourages Impacted Investors To Initiate Dialogue

Accesswire July 22, 2024

Grifols SA Is Under Investigation By The Schall Law Firm And Affected Investors Are Urged To Start Dialogue

Accesswire July 19, 2024